- Will Present Funding for Scientific Trials of Neurocentrx’s Novel Ketamine Prescription Choice for Clinic-to-House Primarily based Care
- Wellcome Funding for a Section 2 Trial in Bipolar Despair Beginning in 2026
- Firm is Pursuing Sequence A Funding for Section 2 and three Trials in Remedy-Resistant Main Despair
EDINBURGH, Scotland–(BUSINESS WIRE)–Neurocentrx Pharma, a clinical-stage biopharmaceutical firm pioneering safer, extra accessible remedies for main psychological well being situations, at the moment introduced the shut of its seed extension funding spherical, which incorporates an award of over $5 million funding from the Wellcome Belief, to speed up the corporate’s scientific improvement packages.
Wellcome’s funding was awarded to help a proof-of-concept Section 2 scientific trial in therapy resistant bipolar melancholy (TR-BPD) beginning in Q1 2026. The trial will consider the protection, tolerability, and efficacy of Neurocentrx’s novel ketamine abuse-deterrent capsule formulation and digital care mixture product, with the aim of advancing towards FDA regulatory approval and the launch of a brand new ketamine prescription choice for suppliers and sufferers to handle home-based melancholy care.
The corporate is at present in search of Sequence A funding to help Section 2 and Section 3 trials in its lead indication, treatment-resistant main depressive dysfunction (TR-MDD).
“This funding displays confidence in our novel method and recognition of the pressing want for progressive psychological well being remedies,” stated Ronald Lindsay, founding director of Neurocentrx. “It positions us to ship a secure, scalable, and efficient therapy mannequin for sufferers dwelling with extreme temper problems worldwide.”
Pioneering Secure, Accessible Ketamine Prescription Remedy
Neurocentrx is growing the primary abuse-deterrent oral ketamine prescription for main psychological well being situations. Its method combines novel formulation know-how with proprietary digital prescription software program to create a regulated clinic-to-home care pathway. Their digital prescription care platform will allow international help for affected person security, supplier communication, and medicine adherence for ketamine-based therapy, in addition to a scalable resolution for different remedies — serving to to optimize care supply for each sufferers and clinicians, whereas sustaining security and scientific efficacy.
In combining digital well being and drug product innovation, Neurocentrx seeks to decrease boundaries to evidence-based prescription ketamine therapy by offering a secure transition from in-clinic to at-home care. The corporate’s method goals to enhance affected person entry to remedy, optimize psychological well being care supply, and improve high quality of life for tens of millions of sufferers with extreme melancholy and temper problems.
About Neurocentrx Pharma.
Headquartered within the UK and with operations throughout the US and Australia, Neurocentrx leverages world-leading scientific specialists and international scientific analysis to speed up its product improvement packages, concentrating on extreme temper problems which are poorly addressed by different remedies. Initially specializing in TR-MDD and TR-BPD, Neurocentrx goals to ship secure, efficient, and accessible psychological well being care worldwide by combining cutting-edge drug formulation applied sciences with a scalable digital prescription care platform.
About Wellcome
Wellcome helps science to resolve the pressing well being challenges dealing with everybody. We help discovery analysis into life, well being and wellbeing, and we’re taking over three worldwide well being challenges: psychological well being, infectious illness and local weather and well being.
Contacts
Investor Relations
Milestone Communications
sara@milestone-advisorsllc.com
- Will Present Funding for Scientific Trials of Neurocentrx’s Novel Ketamine Prescription Choice for Clinic-to-House Primarily based Care
- Wellcome Funding for a Section 2 Trial in Bipolar Despair Beginning in 2026
- Firm is Pursuing Sequence A Funding for Section 2 and three Trials in Remedy-Resistant Main Despair
EDINBURGH, Scotland–(BUSINESS WIRE)–Neurocentrx Pharma, a clinical-stage biopharmaceutical firm pioneering safer, extra accessible remedies for main psychological well being situations, at the moment introduced the shut of its seed extension funding spherical, which incorporates an award of over $5 million funding from the Wellcome Belief, to speed up the corporate’s scientific improvement packages.
Wellcome’s funding was awarded to help a proof-of-concept Section 2 scientific trial in therapy resistant bipolar melancholy (TR-BPD) beginning in Q1 2026. The trial will consider the protection, tolerability, and efficacy of Neurocentrx’s novel ketamine abuse-deterrent capsule formulation and digital care mixture product, with the aim of advancing towards FDA regulatory approval and the launch of a brand new ketamine prescription choice for suppliers and sufferers to handle home-based melancholy care.
The corporate is at present in search of Sequence A funding to help Section 2 and Section 3 trials in its lead indication, treatment-resistant main depressive dysfunction (TR-MDD).
“This funding displays confidence in our novel method and recognition of the pressing want for progressive psychological well being remedies,” stated Ronald Lindsay, founding director of Neurocentrx. “It positions us to ship a secure, scalable, and efficient therapy mannequin for sufferers dwelling with extreme temper problems worldwide.”
Pioneering Secure, Accessible Ketamine Prescription Remedy
Neurocentrx is growing the primary abuse-deterrent oral ketamine prescription for main psychological well being situations. Its method combines novel formulation know-how with proprietary digital prescription software program to create a regulated clinic-to-home care pathway. Their digital prescription care platform will allow international help for affected person security, supplier communication, and medicine adherence for ketamine-based therapy, in addition to a scalable resolution for different remedies — serving to to optimize care supply for each sufferers and clinicians, whereas sustaining security and scientific efficacy.
In combining digital well being and drug product innovation, Neurocentrx seeks to decrease boundaries to evidence-based prescription ketamine therapy by offering a secure transition from in-clinic to at-home care. The corporate’s method goals to enhance affected person entry to remedy, optimize psychological well being care supply, and improve high quality of life for tens of millions of sufferers with extreme melancholy and temper problems.
About Neurocentrx Pharma.
Headquartered within the UK and with operations throughout the US and Australia, Neurocentrx leverages world-leading scientific specialists and international scientific analysis to speed up its product improvement packages, concentrating on extreme temper problems which are poorly addressed by different remedies. Initially specializing in TR-MDD and TR-BPD, Neurocentrx goals to ship secure, efficient, and accessible psychological well being care worldwide by combining cutting-edge drug formulation applied sciences with a scalable digital prescription care platform.
About Wellcome
Wellcome helps science to resolve the pressing well being challenges dealing with everybody. We help discovery analysis into life, well being and wellbeing, and we’re taking over three worldwide well being challenges: psychological well being, infectious illness and local weather and well being.
Contacts
Investor Relations
Milestone Communications
sara@milestone-advisorsllc.com
